Nonoxynol-9 - Generic Drug Details

What are the generic drug sources for nonoxynol-9 and what is the scope of freedom to operate?

Nonoxynol-9 is the generic ingredient in two branded drugs marketed by Personal Prods and Mayer Labs Inc, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for nonoxynol-9

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	49
Clinical Trials:	9
What excipients (inactive ingredients) are in nonoxynol-9?	nonoxynol-9 excipients list
DailyMed Link:	nonoxynol-9 at DailyMed

Recent Clinical Trials for nonoxynol-9

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bayer	Phase 1
CONRAD	Phase 2
Health Decisions	Phase 3

See all nonoxynol-9 clinical trials

US Patents and Regulatory Information for nonoxynol-9

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayer Labs Inc	TODAY	nonoxynol-9	SPONGE;VAGINAL	018683-001	Apr 1, 1983		DISCN	Yes	No
Personal Prods	DELFEN	nonoxynol-9	AEROSOL;VAGINAL	014349-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for nonoxynol-9

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mayer Labs Inc	TODAY	nonoxynol-9	SPONGE;VAGINAL	018683-001	Apr 1, 1983

Nonoxynol-9 Market Dynamics, Financial Trajectory, Regulatory Status, and Commercial Outlook

Last updated: September 18, 2026

Nonoxynol-9 is a mature, low-cost over-the-counter spermicide with declining strategic importance in contraception. The market is fragmented across vaginal films, gels, foams, creams, suppositories, and contraceptive sponges. No major pharmaceutical company reports nonoxynol-9 revenue as a separate product line, and the active ingredient has limited patent-based pricing power. Demand is constrained by competition from condoms, hormonal contraception, intrauterine devices, implants, and emergency contraception, as well as public-health warnings that nonoxynol-9 does not prevent sexually transmitted infections and may increase genital irritation with frequent use.

What is nonoxynol-9 and how is it used?

Nonoxynol-9 is a nonionic surfactant that inactivates sperm by disrupting sperm-cell membranes. It is used as a vaginal contraceptive active ingredient in several dosage forms:

Dosage form	Typical commercial use	Commercial characteristics
Vaginal film	On-demand contraception	Portable, discreet, low manufacturing complexity
Gel or jelly	Applied before intercourse	Low-cost, often sold through OTC and online channels
Foam	Vaginal contraceptive foam	Requires specialized packaging and applicator systems
Cream or suppository	Vaginal spermicide	Longer product-development history
Contraceptive sponge	Device containing nonoxynol-9	Combines barrier and chemical contraception

Nonoxynol-9 is not a systemic drug. It is used immediately before intercourse and must generally be reapplied for each act of intercourse, which limits convenience relative to long-acting contraceptive methods.

In the United States, nonoxynol-9 is regulated through the FDA’s over-the-counter vaginal contraceptive framework rather than through a contemporary branded prescription-drug model. The ingredient is associated with products marketed in concentrations commonly ranging from approximately 2% to 12.5%, depending on dosage form and product design. Labeling and formulation requirements differ by product category.[1]

What is the FDA regulatory status of nonoxynol-9?

Nonoxynol-9 is an established OTC vaginal contraceptive active ingredient. The FDA has recognized vaginal contraceptive products containing nonoxynol-9 within the OTC regulatory framework, subject to applicable monograph, labeling, manufacturing, and safety requirements.[1]

FDA status and market implications

Regulatory issue	Status for nonoxynol-9
Prescription status	Primarily OTC
FDA pathway	OTC monograph framework and applicable product-specific requirements
New drug approval requirement	Generally avoided when the product complies with the applicable OTC framework
Pediatric exclusivity	Not commercially relevant to the mature ingredient
Orphan-drug exclusivity	Not applicable
Biosimilar pathway	Not applicable
Prescription-drug exclusivity	Not applicable
Product-specific clinical differentiation	Limited

The OTC status lowers market-entry barriers. A manufacturer can compete through formulation, packaging, distribution, brand positioning, and consumer marketing rather than through an expensive novel-drug approval strategy.

When does nonoxynol-9 lose exclusivity?

Nonoxynol-9 has no meaningful remaining molecule-level exclusivity. The active ingredient has been commercially available for decades, and generic or private-label competition is structurally possible.

There is no commercially important basic-compound patent blocking ordinary competition. Any current intellectual-property protection is more likely to concern:

• A particular film, gel, applicator, or delivery system
• A contraceptive sponge structure
• Packaging or unit-dose presentation
• Manufacturing processes
• Combination products
• Brand names and trade dress
• Distribution arrangements

These rights do not create broad exclusivity over nonoxynol-9 itself.

Patent and exclusivity profile

Protection category	Commercial position
Composition-of-matter patents	Expired or commercially irrelevant
Active-ingredient exclusivity	None of practical significance
Formulation patents	Possible but narrow and product-specific
Device patents	Possible for sponge or applicator systems
Method-of-use patents	Limited commercial value for conventional contraception
Trademark protection	Material for established brands
Trade-secret protection	Possible for manufacturing and packaging processes

How many patents cover nonoxynol-9 products?

No reliable single count captures all patents associated with nonoxynol-9 products globally. Patent coverage depends on the product, jurisdiction, assignee, dosage form, and search methodology.

The relevant distinction is between patents covering nonoxynol-9 and patents covering a product that happens to contain nonoxynol-9. The first category has little remaining strategic value. The second may include narrow rights involving:

• Film-forming polymers
• Controlled dissolution
• Mucoadhesive formulations
• Applicator geometry
• Sponge materials
• Combination barrier systems
• Packaging that improves stability or dosing accuracy

A patent on a vaginal film or contraceptive device would not ordinarily prevent a competitor from selling a conventional nonoxynol-9 gel or foam. The practical barrier is therefore product-level differentiation, not ingredient-level exclusivity.

What formulations are protected by nonoxynol-9 patents?

The strongest potential formulation protection would involve a delivery system that produces a measurable technical advantage over conventional products. Relevant claim categories may include:

1. A vaginal film with defined polymer composition and dissolution profile.
2. A gel with enhanced retention or reduced leakage.
3. A foam with controlled expansion and dosing characteristics.
4. A sponge with specified pore size, release behavior, or mechanical properties.
5. A combination product pairing nonoxynol-9 with a physical barrier or another contraceptive technology.

Such patents face several limitations. The underlying contraceptive mechanism is old, competing products can use different dosage forms, and the commercial value of a narrow formulation claim is limited when consumers can substitute among gels, films, foams, condoms, and hormonal methods.

What is the market size for nonoxynol-9?

The global nonoxynol-9 market is difficult to quantify because companies generally report sales by brand, contraception category, or consumer-health segment rather than by active ingredient. Public-company filings do not normally disclose nonoxynol-9 revenue separately.

The market is best characterized as a niche OTC contraceptive segment with fragmented distribution. Sales are concentrated in:

• Retail pharmacies
• Mass merchants
• Sexual-health retailers
• E-commerce platforms
• Family-planning clinics
• Public-health and international procurement channels

The product category has limited ability to sustain premium pricing. Unit economics depend on packaging, retail placement, brand recognition, and repeat use rather than on pharmaceutical innovation.

Revenue visibility

Revenue measure	Public visibility
Global nonoxynol-9 revenue	Not generally reported as a standalone figure
Brand-level sales	Inconsistent and often private
Ingredient-level gross margin	Not disclosed
Retail sell-through	Available mainly through commercial market-research databases
Prescription claims data	Limited because products are OTC
Public procurement volumes	Available selectively through tenders and institutional reports

A precise financial trajectory cannot be derived from public issuer disclosures alone. The commercially supportable conclusion is that nonoxynol-9 has a mature, low-growth or declining profile rather than the growth pattern associated with innovative prescription medicines.

What factors are driving nonoxynol-9 market decline?

Competition from more effective or convenient contraception

Nonoxynol-9 competes with methods that have higher effectiveness, longer duration, or greater user convenience. These include:

• Male and female condoms
• Oral contraceptives
• Hormonal implants
• Intrauterine devices
• Injectable contraception
• Vaginal rings
• Emergency contraception
• Permanent contraception

Long-acting reversible contraceptives have altered the competitive environment because they reduce reliance on user-controlled, per-intercourse products. Nonoxynol-9 remains relevant for consumers seeking nonhormonal, on-demand contraception, but that segment is narrower than the total contraception market.

Limited protection against sexually transmitted infections

Nonoxynol-9 does not protect against HIV or other sexually transmitted infections. The CDC and WHO have warned that frequent or repeated use can irritate vaginal and rectal tissue and may increase susceptibility to HIV transmission in high-risk settings.[2][3]

This safety and positioning issue limits the product’s use among consumers who might otherwise seek a dual-purpose contraceptive and infection-prevention product. Condoms have a stronger public-health position because they provide both contraceptive and STI protection when used correctly.

Low switching costs

Consumers can move between brands and dosage forms with little clinical friction. A gel user can switch to a film, foam, condom, or another contraceptive method without a prescriber or diagnostic workup. This keeps pricing competitive and reduces the value of brand loyalty.

Distribution pressure

Retail shelf space increasingly favors high-velocity consumer-health products. Niche spermicides can lose placement to condoms, lubricants, emergency contraception, pregnancy tests, and hormonal products. E-commerce improves product discoverability but also increases price comparison and private-label competition.

Which companies sell or have sold nonoxynol-9 products?

Nonoxynol-9 has been marketed through multiple consumer-health brands and product manufacturers over time. Known product categories include vaginal films, contraceptive gels, foams, suppositories, and sponges.

The commercial landscape has included:

• Brand owners focused on sexual health
• OTC consumer-health companies
• Contract manufacturers
• Pharmacy and retailer private-label businesses
• Family-planning product distributors
• International suppliers

Ownership has changed for several legacy brands, and product availability varies by country. Brand-level ownership should therefore be verified against current FDA labeling, trademark records, and manufacturer disclosures before use in a transaction, diligence report, or litigation analysis.

There is no single dominant innovator controlling the nonoxynol-9 molecule. Competitive advantage is more likely to reside in distribution, brand recognition, product availability, and manufacturing cost.

What patent litigation affects nonoxynol-9?

Nonoxynol-9 is not associated with a major current patent-litigation pattern comparable to blockbuster prescription drugs. The absence of Orange Book-centered litigation is a direct consequence of its OTC status and lack of meaningful molecule-level exclusivity.

Potential disputes would more likely involve:

• Trademark infringement
• Trade dress
• Product labeling
• Advertising claims
• Device or packaging patents
• Contract manufacturing
• Product liability
• Regulatory compliance

Paragraph IV challenge risk

Paragraph IV litigation is not the central generic-entry mechanism for conventional OTC nonoxynol-9 products. Paragraph IV certifications are associated with abbreviated new drug applications for products referencing listed prescription drugs. A nonoxynol-9 product marketed under the OTC framework generally does not create the same Orange Book litigation structure as a prescription drug with listed patents.

What is the Orange Book status of nonoxynol-9?

Nonoxynol-9 is not commercially dependent on an Orange Book patent estate. The FDA Orange Book is designed principally to identify approved drug products and relevant patents for approved applications. Conventional OTC nonoxynol-9 products generally do not have a branded prescription-drug Orange Book profile that would delay generic entry.

The practical consequence is that market access depends on compliance with the applicable OTC requirements, product quality, labeling, and commercial execution rather than on expiration of a listed blockbuster patent.

How strong is the nonoxynol-9 patent estate?

The patent estate is weak at the active-ingredient level and potentially moderate only for narrow product or device claims.

Patent-estate factor	Assessment
Composition-of-matter protection	Very weak or absent
Blocking power over competitors	Low
Formulation differentiation	Possible but narrow
Device protection	Potentially meaningful for specific products
Design-around risk	High
Litigation leverage	Low to moderate
Trademark value	Potentially greater than patent value
Manufacturing know-how	Relevant to cost and quality, not market exclusivity

For investors or licensors, the principal diligence question is not whether nonoxynol-9 is patented. It is whether a specific product has enforceable claims that cover a commercially important delivery system and whether competitors can design around those claims.

How does nonoxynol-9 compare with competing contraceptive products?

Product category	Prescription required	STI protection	User-controlled per use	Long-acting	Patent strength
Nonoxynol-9 spermicide	Usually no	No	Yes	No	Low
Male condom	No	Yes, when used correctly	Yes	No	Low to moderate
Oral contraceptive	Usually yes	No	Daily	No	Product-specific
Hormonal implant	Yes	No	No	Yes	Higher for newer products
IUD	Yes	No	No	Yes	Device and product-specific
Vaginal ring	Usually yes	No	Periodic	No	Product-specific
Emergency contraception	OTC or prescription, depending on product	No	Episodic	No	Product-specific

Nonoxynol-9’s main competitive advantage is access without a prescription and compatibility with consumers who prefer nonhormonal, on-demand contraception. Its disadvantages are lower effectiveness in typical use, repeated application, local irritation, and no STI protection.

What is the financial trajectory for nonoxynol-9?

The financial trajectory is mature and structurally constrained.

Revenue outlook

Revenue is likely to be shaped by four forces:

1. Replacement demand from other contraceptive methods.
2. Stable but limited demand for nonhormonal, on-demand contraception.
3. Price pressure from generic and private-label products.
4. Channel migration from physical retail to e-commerce and specialty sexual-health outlets.

A reasonable commercial classification is:

Metric	Outlook
Market growth	Flat to declining in developed markets
Pricing power	Low
Gross-margin potential	Moderate for branded formats, lower for commodity gels
R&D intensity	Low
Regulatory risk	Moderate because of labeling and safety requirements
Patent-driven upside	Minimal
M&A attractiveness	Brand and distribution dependent
Cash-flow profile	Potentially stable for efficient OTC operators
Blockbuster potential	None

The category may remain profitable for a focused OTC operator with low manufacturing costs and strong distribution. It is unlikely to produce significant value through new molecular development, patent extension, or premium pricing.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are modest for conventional gels and creams. More specialized formats may require:

• Film-casting equipment
• Controlled drying systems
• Unit-dose packaging
• Applicator manufacturing
• Sponge fabrication
• Stability testing
• Microbiological controls
• Packaging compatibility studies

The most relevant barriers are operational. A competitor may legally enter the category but still face difficulties achieving consistent dose delivery, shelf stability, packaging integrity, retail compliance, and acceptable consumer experience.

Manufacturing know-how can support modest margin protection, but it is unlikely to create durable exclusivity without accompanying patents, regulatory approvals, or a strong brand.

What generic launch scenarios exist for nonoxynol-9?

Scenario 1: Commodity OTC entry

A low-cost manufacturer launches a conventional gel, film, or foam through online retailers and regional pharmacies. The likely effect is price erosion, particularly if the product uses standard packaging and makes no differentiated claims.

Scenario 2: Private-label expansion

A retailer or distributor contracts for a private-label spermicide. This strategy can increase shelf access while reducing marketing expense, but it places pressure on branded products.

Scenario 3: Premium delivery format

A manufacturer launches a film, sponge, or applicator with improved convenience. This can support higher pricing if the product achieves reliable consumer adoption, though the product remains exposed to substitution from condoms and other contraceptives.

Scenario 4: Market exit by a legacy brand

A brand owner discontinues a low-volume SKU because of declining retail velocity, packaging costs, or limited marketing return. This can create temporary supply shortages without changing the long-term category outlook.

What licensing deals involve nonoxynol-9?

Nonoxynol-9 does not have the licensing profile of a novel prescription medicine. Royalty-bearing deals are more likely to concern:

• A branded product
• A contraceptive sponge or applicator
• A film or controlled-release platform
• Geographic distribution
• Contract manufacturing
• Private-label supply

The commercial value of a licensing transaction would depend primarily on brand reach, retail access, product registrations, manufacturing capacity, and territory rights. A license limited to the active ingredient would have little value because nonoxynol-9 is widely available and lacks meaningful molecule-level exclusivity.

What geographic markets remain commercially relevant?

Demand is likely to be strongest where consumers seek:

• Nonhormonal contraception
• Low-cost OTC products
• Discreet, on-demand contraception
• Products distributed through pharmacies or family-planning programs
• Contraception without physician access

Developed markets have greater competition from hormonal and long-acting methods. Lower-income markets may retain demand for inexpensive, user-controlled products, but procurement economics and public-health guidance remain important.

Country-level market access depends on local registration, labeling, import controls, quality standards, and whether the jurisdiction recognizes an OTC monograph-style pathway. U.S. regulatory status does not automatically establish authorization elsewhere.

Key Takeaways

• Nonoxynol-9 is a mature OTC spermicide with no meaningful molecule-level exclusivity.
• Its main products include films, gels, foams, creams, suppositories, and contraceptive sponges.
• The FDA regulates conventional products through the OTC vaginal contraceptive framework.
• Orange Book and Paragraph IV litigation are generally not the principal market-access issues.
• Product-level patents may cover films, sponges, applicators, packaging, or specialized formulations, but these rights are narrow and design-around risk is high.
• Nonoxynol-9 has no biosimilar risk because it is a small-molecule chemical contraceptive, not a biologic.
• Revenue is fragmented and not generally disclosed by active ingredient.
• The market is likely flat to declining in developed countries, with price pressure from generic and private-label products.
• Commercial value lies in brand, distribution, manufacturing efficiency, and product format rather than in patent protection.
• The strongest competitive alternatives are condoms, oral contraceptives, implants, intrauterine devices, vaginal rings, and emergency contraception.

FAQs

Is nonoxynol-9 still commercially available?

Yes. It remains available in selected OTC vaginal contraceptive products, although availability varies by country, brand, retailer, and dosage form.

Can nonoxynol-9 be used with condoms?

Some nonoxynol-9 products are designed for use with condoms, but compatibility depends on the specific product and condom material. Product labeling controls.

Does nonoxynol-9 prevent HIV or sexually transmitted infections?

No. Nonoxynol-9 is a contraceptive spermicide and does not provide STI protection. Frequent use may cause irritation that increases vulnerability to HIV transmission in high-risk circumstances.[2][3]

Is nonoxynol-9 more profitable than condoms?

There is no general public financial dataset that supports a direct ingredient-level profitability comparison. Nonoxynol-9 products can achieve attractive margins in branded or specialized formats, but condoms generally have broader consumer demand and stronger STI-prevention positioning.

Can a company launch a generic nonoxynol-9 product?

A company can pursue an OTC product strategy if it satisfies applicable FDA requirements, including active-ingredient, dosage-form, labeling, manufacturing, packaging, and quality requirements. The absence of broad molecule-level exclusivity reduces patent barriers, but regulatory compliance and distribution remain necessary.

References

1. U.S. Food and Drug Administration. (2023). Over-the-counter human drugs: Vaginal contraceptive drug products. Code of Federal Regulations, 21 C.F.R. § 310.545.

2. Centers for Disease Control and Prevention. (2021). Sexually transmitted infections treatment guidelines, 2021: Prevention methods. U.S. Department of Health and Human Services.

3. World Health Organization. (2002). Results of a randomized controlled trial of nonoxynol-9 vaginal gel on the incidence of HIV infection. World Health Organization.